Stay updated on Selumetinib with Vinblastine in Low-Grade Glioma Clinical Trial
Sign up to get notified when there's something new on the Selumetinib with Vinblastine in Low-Grade Glioma Clinical Trial page.

Latest updates to the Selumetinib with Vinblastine in Low-Grade Glioma Clinical Trial page
- Check3 days agoChange DetectedRevision update: new entries dated 2026-02-12 and 2026-02-13 with Revision: v3.4.2, replacing the previous Revision: v3.4.1. These changes are administrative and do not affect core study details or eligibility.SummaryDifference0.1%

- Check10 days agoChange DetectedPage revision updated to v3.4.1 on 2026-02-06 (with related updates on 2026-02-05 and 2026-02), replacing v3.4.0. This appears to be an administrative/versioning update and does not modify core trial details, eligibility criteria, or outcomes.SummaryDifference0.1%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedUI updates add a 'Show glossary' option and refresh QC-related metadata (Last Update Submitted that Met QC Criteria and Last Update Posted); the No FEAR Act Data label appears and the revision tag is updated to v3.4.0.SummaryDifference0.1%

- Check31 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4; no visible changes to trial details or eligibility. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check59 days agoChange DetectedLocations section expanded to list numerous US states and Canadian provinces, with revision tag v3.3.3. The update reorganizes location data for the study.SummaryDifference2%

- Check81 days agoChange DetectedThe page now displays Revision: v3.3.2, replacing Revision: v3.3.1. No substantive study details or page functionality are affected.SummaryDifference0.0%

Stay in the know with updates to Selumetinib with Vinblastine in Low-Grade Glioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selumetinib with Vinblastine in Low-Grade Glioma Clinical Trial page.